Kuros Biosciences AG's Annual General Meeting Concludes Successfully

Kuros Biosciences AG, a leader in innovative bone graft technologies, held its Annual General Meeting on April 17, 2024, in Schlieren, Zurich. The meeting saw the approval of key financial and governance matters for the year 2023. Shareholders ratified the Annual Report, Financial Statements, and Consolidated Financial Statements, acknowledging the Auditors' Reports.

Additionally, the meeting featured the re-election of Clemens van Blitterswijk as Chairman and the re-election of Joost de Bruijn and Oliver Walker as Board members. New Board members Albert Arp and Chris Fair, CEO, were welcomed. The compensation for the Board and Executive Committee was approved, and new adjustments to corporate bylaws were adopted, including changes in share capital conditions favorable to employees and board members.

The event was notably attended by representatives for 60.4% of the total shares. PricewaterhouseCoopers Ltd was reappointed as the company's auditor. Legal firm Keller AG will continue as an independent proxy.